The MONARCH trial suggested a significantly higher incidence of neutropenia in patients receiving 200 mg<unk>  every 2 weeks, compared to patients being treated with adalimumab (13.6% vs 0.5%). However, infection rates were similar between both groups (28.8% vs 27.7%). Other common side effects that occurred in 1% to 10% of patients included thrombocytopenia (low platelet count), infections of the upper respiratory tract and the urinary tract, oral herpes, hyperlipidaemia, and reactions at the injection site.
Sarilumab
Emapalumab
Burosumab
Olaratumab
Dupilumab
Evolocumab
Anifrolumab
Alirocumab